Movement Alert|Genmab A/S Overnight Rise 5.68%, Q3 earnings beat and Petosemtamab phase 3 progress remained in focus

Market Focus
Nov 10

On November 10, Genmab A/S saw an Overnight rise of 5.68%, trading at $58.97. The move appeared to extend recent strength after investors continued to digest the company’s quarterly earnings beat and positive late-stage oncology trial updates.

Genmab A/S previously reported third-quarter earnings per share of $5.51, well above the $3.59 consensus estimate, while revenue was $1.187 billion versus the $1.194 billion estimate. The profit outperformance pointed to stronger-than-expected earnings delivery even as sales came in slightly below forecasts.

Pipeline developments remained an additional catalyst. The company said its phase 3 LiGeR-HN1 trial showed Petosemtamab plus pembrolizumab met both primary endpoints in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma, with the combination reducing the risk of death by 50% versus pembrolizumab alone. The company has said it plans to engage with regulators globally following the result.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10